Article Type
Changed
Thu, 03/19/2020 - 15:46

Key clinical point: Serum 25(OH)D levels are associated with a modest decrease in relapse rate and radiological inflammatory activities in patients with early relapsing multiple sclerosis (MS).

Major finding: Each 25 nmol/L increase in serum 25(OH)D levels is associated with a decrease in clinical relapse rate (risk ratio [RR], 0.90), gadolinium-enhancing lesions (RR, 0.69), new/enlarging T2 lesions (RR, 0.86), and new active lesions (RR, 0.81) in the magnetic resonance imaging. 

Study details: Meta-analysis of 13 studies including 3,498 patients.

Disclosures: No study sponsor was identified.

Citation: Martínez-Lapiscina EH et al. J Neurol Sci. 2020 Jan 25. doi: 10.1016/j.jns.2020.116668.

Publications
Topics
Sections

Key clinical point: Serum 25(OH)D levels are associated with a modest decrease in relapse rate and radiological inflammatory activities in patients with early relapsing multiple sclerosis (MS).

Major finding: Each 25 nmol/L increase in serum 25(OH)D levels is associated with a decrease in clinical relapse rate (risk ratio [RR], 0.90), gadolinium-enhancing lesions (RR, 0.69), new/enlarging T2 lesions (RR, 0.86), and new active lesions (RR, 0.81) in the magnetic resonance imaging. 

Study details: Meta-analysis of 13 studies including 3,498 patients.

Disclosures: No study sponsor was identified.

Citation: Martínez-Lapiscina EH et al. J Neurol Sci. 2020 Jan 25. doi: 10.1016/j.jns.2020.116668.

Key clinical point: Serum 25(OH)D levels are associated with a modest decrease in relapse rate and radiological inflammatory activities in patients with early relapsing multiple sclerosis (MS).

Major finding: Each 25 nmol/L increase in serum 25(OH)D levels is associated with a decrease in clinical relapse rate (risk ratio [RR], 0.90), gadolinium-enhancing lesions (RR, 0.69), new/enlarging T2 lesions (RR, 0.86), and new active lesions (RR, 0.81) in the magnetic resonance imaging. 

Study details: Meta-analysis of 13 studies including 3,498 patients.

Disclosures: No study sponsor was identified.

Citation: Martínez-Lapiscina EH et al. J Neurol Sci. 2020 Jan 25. doi: 10.1016/j.jns.2020.116668.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Thu, 03/19/2020 - 15:45
Un-Gate On Date
Thu, 03/19/2020 - 15:45
Use ProPublica
CFC Schedule Remove Status
Thu, 03/19/2020 - 15:45
Hide sidebar & use full width
render the right sidebar.